The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

Globe Investor

News Sources

Take control of your investments with the latest investing news and analysis

Press release from Business Wire

Glancy Binkow & Goldberg LLP Announces Investigation of Questcor Pharmaceuticals, Inc.

Friday, September 28, 2012

Glancy Binkow & Goldberg LLP Announces Investigation of Questcor Pharmaceuticals, Inc.20:36 EDT Friday, September 28, 2012 LOS ANGELES (Business Wire) -- Glancy Binkow & Goldberg LLP announces that it is investigating potential claims on behalf of purchasers of the common stock of Questcor Pharmaceuticals, Inc. (“Questcor” or the “Company”) (NASDAQ:QCOR) concerning possible violations of federal securities laws. The investigation focuses on allegations that certain statements issued by Questcor between April 26, 2011 and September 21, 2012 were false and misleading concerning the Company's business and financial prospects. Questcor is a biopharmaceutical company that provides prescription drugs for the treatment of multiple sclerosis, nephrotic syndrome and infantile spasms indications. The Company primarily offers H.P. Acthar Gel, an injectable drug for the treatment of acute exacerbations of multiple sclerosis in adults. The investigation concerns allegations that the Company and certain of its executive officers violated federal securities laws by issuing false and misleading statements about the effectiveness of Acthar as a treatment for multiple sclerosis and nephrotic syndrome. On September 24, 2012 Questcor disclosed that the U.S. government has undertaken an investigation into the Company's promotional practices. Following this news, the price of Questcor stock dropped 37%, or $11.05 per share, to close at $19.08 per share on September 24, 2012. If you purchased Questcor common stock between October April 26, 2011 and September 21, 2012, if you have information or would like to learn more about these claims, or if you wish to discuss these matters or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Michael Goldberg, Esquire, of Glancy Binkow & Goldberg LLP, 1925 Century Park East, Suite 2100, Los Angeles, California 90067, by telephone at 310-201-9150, Toll-Free at 888-773-9224, by e-mail to shareholders@glancylaw.com, or visit our website at http://www.glancylaw.com. This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules. Glancy Binkow & Goldberg LLP, Los Angeles, CAMichael Goldberg310-201-9150 or 888-773-9224shareholders@glancylaw.comwww.glancylaw.com